References
- Amend K, Hicks D, Ambrosone CB. 2006. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 66: 8327- 8330. https://doi.org/10.1158/0008-5472.CAN-06-1927
-
Baichwal VR, Baeuerle PA. 1997. Activate NF-
$\kappa{B}$ or die? Curr. Biol. 7: R94-R96. https://doi.org/10.1016/S0960-9822(06)00046-7 - Bryan BB, Schnitt SJ, Collins LC. 2006. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod. Pathol. 19: 617-621. https://doi.org/10.1038/modpathol.3800570
- Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, et al. 2012. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 14: R62. https://doi.org/10.1186/bcr3168
- Chiosis G, Vilenchik M, Kim J, Solit D. 2004. Hsp90: the vulnerable chaperone. Drug Discov. Today 9: 881-888. https://doi.org/10.1016/S1359-6446(04)03245-3
- Da Silva VC, Ramos CH. 2012. The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics. J. Proteomics 75: 2790-2802. https://doi.org/10.1016/j.jprot.2011.12.028
- Groblewska M, Siewko M, Mroczko B, Szmitkowski M. 2012. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem. Cytobiol. 50: 12-19. https://doi.org/10.5603/FHC.2012.0002
- Han HZ. 2012. Research in progress of triple negative breast cancer molecular targeted therapy. Chinese Clin. Oncol. 17: 470-474.
- Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, et al. 2008. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14: 7940-7946. https://doi.org/10.1158/1078-0432.CCR-08-0221
- Hong YS, Lee D, Kim W, Jeong JK, Kim CG, Sohng JK, et al. 2004. Inactivation of the carbamoyltransferase gene refines post-polyketide synthase modification steps in the biosynthesis of the antitumor agent geldanamycin. J. Am. Chem. Soc. 126: 11142-11143. https://doi.org/10.1021/ja047769m
- Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 69: 5898-5903.
- Kim MS, Kwak HJ, Lee JW, Kim HJ, Park MJ, Park JB, et al. 2008. 17-Allylamino-17-demethoxygeldanamycin down-regulates hyaluronic acid-induced glioma invasion by blocking matrix metalloproteinase-9 secretion. Mol. Cancer Res. 6: 1657-1665. https://doi.org/10.1158/1541-7786.MCR-08-0034
- Kim W, Lee D, Hong SS, Na Z, Shin JC, Roh SH, et al. 2009. Rational biosynthetic engineering for optimization of geldanamycin analogues. Chembiochem. 10: 1243-1251. https://doi.org/10.1002/cbic.200800763
- Kim W, Lee JS, Lee D, Cai XF, Shin JC, Lee K, et al. 2007. Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring. Chembiochem. 8: 1491-1494. https://doi.org/10.1002/cbic.200700196
- Messaoudi S, Peyrat JF, Brion JD, Alami M. 2011. Heat shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010. Expert Opin. Ther. Pat. 21: 1501-1542. https://doi.org/10.1517/13543776.2011.594041
- Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63. https://doi.org/10.1016/0022-1759(83)90303-4
- Mosser DD, Morimoto RI. 2004. Molecular chaperones and the stress of oncogenesis. Oncogene 23: 2907-2918. https://doi.org/10.1038/sj.onc.1207529
- Sankhala KK, Mita MM, Mita AC, Takimoto CH. 2011. Heat shock proteins: a potential anticancer target. Curr. Drug Targets 12: 2001-2008. https://doi.org/10.2174/138945011798829339
- Shin JC, Zhu N, Lee DH, Kim WC, Lee K, Shen YM, et al. 2008. Characterization of tailoring genes involved in the modification of geldanamycin polyketide in Streptomyces hygroscopicus JCM4427. J. Microbiol. Biotechnol. 18: 1101-1108.
- Whitesell L, Lindquist SL. 2005. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 5: 761-772. https://doi.org/10.1038/nrc1716
- Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. 1994. Inhibition of heat shock protein 90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91: 8324-8328. https://doi.org/10.1073/pnas.91.18.8324
- Wu CZ, Jang JH, Ahn JS, Hong YS. 2012. New geldanamycin analogs from Streptomyces hygroscopicus. J. Microbiol. Biotechnol. 22: 1478-1481. https://doi.org/10.4014/jmb.1206.06026
- Wu CZ, Jang JH, Woo M, Ahn JS, Kim SJ, Hong YS. 2012. Enzymatic glycosylation of nonbenzoquinone geldanamycin analogs via Bacillus UDP-glycosyltransferase. Appl. Environ. Microbiol. 78: 7680-7686. https://doi.org/10.1128/AEM.02004-12
- Wrona IE, Gozman A, Taldone T, Chiosis G, Panek JS. 2010. Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90. J. Org. Chem. 75: 2820-2835. https://doi.org/10.1021/jo1000109
- Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, et al. 2008. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer 122: 2050-2056. https://doi.org/10.1002/ijc.23337
- Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, et al. 2008. Activation of fibronectin/PI3K/Akt leads to chemoresistance to docetaxel by regulating surviving protein expression in ovarian and breast cancer. Cancer Lett. 261: 108-119. https://doi.org/10.1016/j.canlet.2007.11.022
- Zhang H, Burrows F. 2004. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 82: 488-499.
- Zhao S, Ma W, Zhang M, Tang D, Shi Q, Xu S, et al. 2013. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med. Oncol. 30: 335. https://doi.org/10.1007/s12032-012-0335-4
Cited by
- Identifying Differentially Expressed Genes and Screening Small Molecule Drugs for Lapatinib-resistance of Breast Cancer by a Bioinformatics Strategy vol.15, pp.24, 2014, https://doi.org/10.7314/apjcp.2014.15.24.10847
- 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells vol.47, pp.5, 2014, https://doi.org/10.1007/s10863-015-9620-1
- Targeting Cell Survival Proteins for Cancer Cell Death vol.9, pp.1, 2014, https://doi.org/10.3390/ph9010011
- Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells vol.35, pp.1, 2014, https://doi.org/10.1186/s13046-016-0428-6
- Targeting cancer cell mitochondria as a therapeutic approach: recent updates vol.9, pp.9, 2014, https://doi.org/10.4155/fmc-2017-0011
- Non-Benzoquinone Geldanamycin Analog, WK-88-1, Induces Apoptosis in Human Breast Cancer Cell Lines vol.28, pp.4, 2014, https://doi.org/10.4014/jmb.1710.10063
- Reblastatins Inhibit Phenotypic Changes of Monocytes/Macrophages in a Milieu Rich in 27-Hydroxycholesterol vol.20, pp.2, 2014, https://doi.org/10.4110/in.2020.20.e17
- Small-Molecule Drug Discovery in Triple Negative Breast Cancer: Current Situation and Future Directions vol.64, pp.5, 2014, https://doi.org/10.1021/acs.jmedchem.0c01180